In this episode, Henry Jennings is joined by Dr Megan Baldwin, CEO and Managing Director at Opthea Limited (ASX/NASDAQ: OPT). OPT is a biopharmaceutical company committed to improving vision in patients suffering from retinal eye diseases. They are developing a novel therapeutic to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME), which is soon heading for Phase III clinical trials. Dr Megan Baldwin was appointed CEO and Managing Director at Opthea Limited (formerly Circadian Technologies) in February 2014, and has over 20 years' experience focusing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. It has just been announced that she is now moving to Chief Innovation Officer and Founder, as the board has appointed a new CEO and CFO with more experience in commercialisation. Looks like a smart move from OPT.

---

Marcus Today contains stock market education, commentary and actionable ideas.

Sign up for a no-obligation 14-day free trial - click here.

Prior to Opthea, she was employed at Genentech (now Roche), the world leader in the field of angiogenesis-based therapies for cancer and other diseases. Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech’s commercial division, and having responsibility for corporate competitive intelligence activities. In these roles, Megan developed extensive commercial and scientific knowledge in the field of anti-angiogenic and oncology drug development. Megan holds a PhD in Medicine from the University of Melbourne. Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast. Why not sign up for a free trial? Get access to expert insights and research and become a better investor.